We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02964208
Previous Study | Return to List | Next Study

AMPLATZER™ LAA Occluder Post Approval Study (PAS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02964208
Recruitment Status : Active, not recruiting
First Posted : November 16, 2016
Last Update Posted : August 2, 2022
Information provided by (Responsible Party):
Abbott Medical Devices

Brief Summary:
The AMPLATZER LAA Occluder is a transcatheter, self-expanding nitinol device intended for use in preventing thrombus embolization from the LAA. The purpose of this study is to compile real world outcome data on the use of AMPLATZER LAA Occluder in subjects with non-valvular atrial fibrillation (NVAF)

Condition or disease Intervention/treatment
Atrial Fibrillation Thromboembolism Stroke Device: AMPLATZER™ LAA Occluder

Detailed Description:
The AMPLATZER LAA Occluder device will be clinically evaluated through this post approval study. This is a non-randomized multicenter study on patients who have undergone a procedure to implant an AMPLATZER LAA Occluder or will undergo an implant of an AMPLATZER LAA Occluder.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: AMPLATZER™ LAA Occluder Post Approval Study (PAS)
Actual Study Start Date : December 9, 2016
Actual Primary Completion Date : June 30, 2020
Estimated Study Completion Date : June 30, 2023

Resource links provided by the National Library of Medicine

Intervention Details:
  • Device: AMPLATZER™ LAA Occluder
    The AMPLATZER™ LAA Occluder is intended to prevent thrombus embolization from the left atrial appendage (LAA) in patients who have nonvalvular Atrial Fibrillation (AF). It may be considered for use in patients who have a high risk of stroke and bleeding and are deemed by their physician to have an appropriate rationale to seek a non-pharmacologic alternative to long term anticoagulants.
    Other Names:
    • AMPLATZER™ Cardiac Plug™
    • AMPLATZER™ Amulet™

Primary Outcome Measures :
  1. The occurrence of one or more adverse events listed in description below [ Time Frame: Implant through 24 months ]
    The occurrence of one or more the composite of stroke (including ischemic or hemorrhagic), systemic embolism, or cardiovascular or unexplained death at 24 months from the time of enrollment

  2. The occurrence of ischemic stroke or systemic embolism as listed in description below. [ Time Frame: Implant through 24 months ]
    The occurrence of ischemic stroke or systemic embolism at 24 months from the time of enrollment

  3. The occurrence of a major adverse event within 7 days [ Time Frame: Implant through 7 days ]
    The occurrence of one of the following events between the time of implant and within 7 days of the procedure or by hospital discharge, whichever is later: all-cause death, ischemic stroke, systemic embolism, or device or procedure-related events requiring open cardiac surgery or major endovascular repair

Secondary Outcome Measures :
  1. Comparison of the observed rate of ischemic stroke at 24months with the CHA2DS2-VASc predicted rate [ Time Frame: Implant through 24 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The subject population will include participants that are > 18 years old and diagnosed with NVAF.

Inclusion Criteria:

  • 18 years of age or older
  • Documented history of nonvalvular atrial fibrillation
  • Subjects in whom an AMPLATZER LAA Occluder device is intended to be implanted or Subjects who underwent an AMPLATZER LAA Occluder implant attempt after the device was approved in the applicable geography

Exclusion Criteria:

  • Women of childbearing potential who are, or plan to become, pregnant during the time of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02964208

Show Show 22 study locations
Sponsors and Collaborators
Abbott Medical Devices
Layout table for investigator information
Study Director: Maren Wagner Abbott
Layout table for additonal information
Responsible Party: Abbott Medical Devices
ClinicalTrials.gov Identifier: NCT02964208    
Other Study ID Numbers: SJM-CIP-10122
First Posted: November 16, 2016    Key Record Dates
Last Update Posted: August 2, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Abbott Medical Devices:
Atrial Fibrillation
Left Atrial Appendage
Cardiac Plug
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Vascular Diseases
Cardiovascular Diseases
Arrhythmias, Cardiac
Heart Diseases
Pathologic Processes
Embolism and Thrombosis